Optimizing Drug Delivery for Modern Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Optimizing Drug Delivery for Modern Biologics
The author discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.


Pharmaceutical Technology
Volume 36, Issue 5, pp. 82-84

Addressing the challenges

Potential solutions would be to increase the dose concentration to fit within the classic 1-mL volume limitation, or to expand the dose to a larger volume. Concentration has apparently been the choice for many products to date because dosages have increased in the cases of products like Bristol-Myers Squibb's Orencia, although the 1-mL paradigm has not been broken. In fact, some recently introduced self-injected products, such as UCB's Cimzia, have concentrations of up to 200 mg/mL.

The exponential relationship between product concentration and viscosity, which often becomes readily apparent above 100 mg/mL, may limit this strategy significantly because the product either may not be deliverable by self-injection or may not be amenable to existing fill–finish processes if it is too viscous. Concentration to the necessary level in the final product may not be possible for all products because in many cases, upstream purification and manufacturing processes may limit the maximum concentration for the final drug product more than delivery and fill–finish process concerns. Additionally, drug-product properties, such as pH and osmolality, along with the use of certain excipients, may limit the most appropriate drug-product concentration. These properties may need to be kept within certain ranges to prevent patient discomfort and site reaction upon injection. Certain emerging formulation technologies, including the use of nonaqueous solutions, have shown promise towards mitigating such concerns, but are awaiting regulatory approval.

Increasing the administered volume of drug product offers the ability to deliver a larger dose, but this approach can have disadvantages. There are limitations to how rapidly a volume of drug can be injected subcutaneously. Although the optimal injection time may vary greatly by individual drug product, and the literature regarding the relationship between injection volume and speed is limited, the subcutaneous space cannot necessarily tolerate rapidly injecting larger and larger dose volumes as tissue disruption and site reaction may occur. Second, if the injection is rapid and the volume is too large, there is potential for the product to leak back from the injection site, reducing the bioavailability relative to the total dose. Lastly, a larger volume of product may require a larger device for self-delivery, and, potentially, a longer injection time, neither of which is likely to be desirable, especially in a crowded therapeutic class.

A potential solution to large-volume injection challenges is the development and use of systems that administer the dose into the subcutaneous space more slowly. Such systems have the potential to expand the possibilities for self-injection. Due to the longer duration of injection, the device or system may need to be temporarily attached to the body at an appropriate injection site; thus, the current industry interest in patch-injection technologies.

Such systems use a bladder, cartridge, or other container for the drug product, which may either be prefilled or user-filled. The mechanism to force the drug product into the body may be purely mechanical or electromechanical. Due to the widely varying properties of drug products, which can influence the optimal injection time, systems should be easily adaptable to the demands of the drug-product developer (e.g., changing the system mechanism or varying the programming of an electromechanical system).

Patch-injector systems specifically can potentially allow for less frequent administration of products already approved for self-injection and for porting of products approved for IV administration to subcutaneous self-injection. In the case of the former, a larger dose can be given by a single injection less frequently than currently approved, more frequent regimens, except in the case where dose-limiting toxicities may exist. The latter can be performed by concentrating the existing formulation or by using the already formulated dosage strength in conjunction with a larger-volume injection.

Technologies that allow for delivery of higher drug product doses may be applicable to certain emerging needs for mAb products. For instance, the potential to coformulate (i.e., containing more than one mAb product in a single dose), may be a significant area of investigation to create next-generation therapeutic options. A major limitation for some solutions is viscosity, which can be significantly higher than would be expected for a normal mAb solution. The ability to deliver such products in higher volumes may increase the attractiveness of pursuing combination drug products.

Conclusion

In conclusion, the development of mAb products to address patient needs is complicated by the many physical and chemical factors inherent to such drug-product solutions. Limitations imposed by existing formulation strategies and the dose volume that can be delivered by devices may make some products less attractive than currently approved therapies or less likely to gain user acceptance, even in areas of unmet need. Innovative delivery systems that address the challenges of higher-volume delivery may enable drug manufacturers to develop products that use more desirable dosing and IV administration regimens.

Bart E. Burgess is manager of business development, self-injection systems, at West Pharmaceutical Services, tel. 610.594.3295,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here